Evidence map›Paper›PMID 36406239›Full record

ArticleJournal of King Saud University. Science2023

Masitinib analogues with the

Arun Bahadur Gurung, Mohammad Ajmal Ali, Reem M Aljowaie, Saeedah M Almutairi, Hiba Sami, Joongku Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of King Saud University. Science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Arun Bahadur GurungDepartment of Basic Sciences and Social Sciences, North-Eastern Hill University, Shillong 793022, Meghalaya, India.
Mohammad Ajmal AliDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Reem M AljowaieDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Saeedah M AlmutairiDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Hiba SamiDepartment of Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh 202002, India.
Joongku LeeDepartment of Environment and Forest Resources, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.
King Saud University · SAChungnam National University · KRJawaharlal Nehru Medical College Hospital · INNorth Eastern Hill University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Masitinib is an orally acceptable tyrosine kinase inhibitor that is currently investigated under clinical trials against cancer, asthma, Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis. A recent study confirmed the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity of masitinib through inhibition of the main protease (M

Indexed as

CoronavirusCOVID-19Main protease inhibitorsMasitinibMasitinib analoguesMolecular dynamics simulationsN-methylpiperazineSARS-CoV-2

Identifiers

PMID36406239
PMCPMC9651948
OpenAlexW4307901039

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.